已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

医学 内科学 共病 糖尿病 骨髓增生异常综合症 人口 骨髓 环境卫生 内分泌学
作者
Massimo Breccia,Vincenzo Federico,Giuseppina Loglisci,Roberto Latagliata,Michelina Santopietro,Adriano Salaroli,Alessandra Serrao,Gioia Colafigli,Agostino Tafuri,Giuliana Alimena
出处
期刊:Blood [Elsevier BV]
卷期号:118 (21): 3793-3793 被引量:1
标识
DOI:10.1182/blood.v118.21.3793.3793
摘要

Abstract Abstract 3793 MDS-specific comorbidity index (MDS-CI) is a score reported by the Pavia group for myelodysplastic syndromes (MDS) patients. This score is a time-dependent index developed for predicting the effect of comorbidities on outcome of these subjects. We applied this score on a total of 450 MDS patients: comorbidities were recorded at the time of diagnosis and considered by medical staff for the analysis. All patients were consecutively diagnosed and followed at our institute in a period between January 1992 and December 2006. Statistical analysis was carried out using SPSS software; survival was defined as time from diagnosis to last contact or death for any cause. Median age of the whole population was 69 years (range 21–88), with a prevalence of male sex (ratio m/f 1.6). Overall, we found the presence of one or more comorbidities in 94% of the examined patients. The most common comorbidities were cardiac disorders observed in 40% of patients, followed by diabetes with organ damage recorded in 22 cases. Application of MDS-CI score identified 300 patients with score 0, 55 patients with score 1, 80 patients with score 2 and 15 patients with score >2. We found significant differences in OS according to MDS-CI stratification: from 38 months for low risk patients (score 0) to 22 months for high-risk patients (score >2, p=0.02). We then evaluated the prognostic effect of MDS-CI on patients stratified according to WPSS prognostic index. WPSS application was possible in 330 of 450 patients who entered the analysis (73%), due to cytogenetic availability of data: we identified 112 patients (34%) with very low/low risk, 137 patients (41.5%) with intermediate risk and 81 patients (24.5%) with high/very high risk. As reported by the Pavia group, we assessed prognostic relevance of comorbidities in very low/low risk WPSS patients, intermediate and high/very high-risk patients. We found in the first category a significant difference in OS stratification: from 48.5 months for patients with score 0 to 20.4 months for patients with score >2 (p=0.002). In WPSS intermediate risk we found similar significant OS difference: from 32.3 months for patients with score 0 to 18.3 months for patients with score 2 (p=0.001). Conversely, we did not find significant differences in WPSS high/very high-risk patients. We also found significant correlations between presence of comorbidities at baseline, as stratified with MDS-CI, and risk of non-leukemic death: from 22% in patients without comorbidities to 75% in patients with score >2 according to MDS-CI (p=0.002). Our analysis showed the efficacy of MDS-CI on a large series of MDS consecutively seen, diagnosed and followed in a single center while strengthening the results reported by the Pavia group: in fact, the value of comorbidities was confirmed in a cohort of patients similar to that observed in the original paper, in terms of median age (69 years in our series vs 66 years in the Pavia series), but with higher percentage of patients with intermediate WPSS risk (41.5% in our series vs 18% in the Pavia population). MDS-CI is a very valid tool capable to differentiate MDS patients with very low/low and intermediate WPSS risk in terms of OS and non-leukemic death risk. Disclosures: Alimena: Novartis: Honoraria; Bristol Myers Squibb: Honoraria.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Calyn完成签到 ,获得积分0
4秒前
高兴的忆曼完成签到,获得积分10
8秒前
淡淡的向雁完成签到,获得积分10
11秒前
23秒前
xiaolang2004完成签到,获得积分10
24秒前
胡萝卜完成签到,获得积分10
29秒前
专一的咖啡完成签到,获得积分10
40秒前
Akim应助hume采纳,获得10
45秒前
yuan完成签到 ,获得积分10
52秒前
akakns完成签到 ,获得积分10
1分钟前
罐罐完成签到,获得积分10
1分钟前
六六完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
直觉应助科研达人采纳,获得10
1分钟前
Cain完成签到,获得积分10
1分钟前
叮当拉卡给叮当拉卡的求助进行了留言
1分钟前
和谐的冬莲完成签到 ,获得积分10
1分钟前
Li发布了新的文献求助10
1分钟前
水若琳发布了新的文献求助10
1分钟前
隐形曼青应助背后的鞋垫采纳,获得10
1分钟前
lab完成签到 ,获得积分0
1分钟前
wch666完成签到,获得积分10
1分钟前
GingerF完成签到,获得积分0
1分钟前
NZC完成签到,获得积分10
1分钟前
luroa完成签到 ,获得积分10
1分钟前
英俊的铭应助风吹屁屁凉采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
科目三应助wch666采纳,获得10
1分钟前
轻语完成签到 ,获得积分10
1分钟前
张建威完成签到,获得积分10
1分钟前
bkagyin应助小刘采纳,获得10
1分钟前
1分钟前
调皮的灰狼完成签到,获得积分10
1分钟前
1分钟前
litieniu发布了新的文献求助10
1分钟前
1分钟前
感谢有你完成签到 ,获得积分10
1分钟前
1分钟前
CodeCraft应助科研达人采纳,获得10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990008
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256121
捐赠科研通 3270913
什么是DOI,文献DOI怎么找? 1805105
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216